ETRA 8-K: SEC filing

Electra Therapeutics

Filed with the SEC on · accession 0001193125-26-458464

ETRA filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Electra Therapeutics issued a press release announcing its financial results for the quarter ended September 30, 2026, furnished under Item 2.02 of Form 8-K.

Key details

RegistrantElectra Therapeutics, Inc.
President and chief executive officerQuehuong (Kathy) Dong

✦ Ask GOAX AI about this filing — what it means for ETRA, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ETRA?

Click here

Frequently asked questions

What did ETRA file with the SEC on Nov 12, 2026?

ETRA filed a 8-K (SEC filing). Electra Therapeutics issued a press release announcing its financial results for the quarter ended September 30, 2026, furnished under Item 2.02 of Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other ETRA SEC filings

Get alerts when ETRA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days